Literature DB >> 20684594

Phenylsulfonylfuroxans as modulators of multidrug-resistance-associated protein-1 and P-glycoprotein.

Roberta Fruttero1, Marco Crosetti, Konstantin Chegaev, Stefano Guglielmo, Alberto Gasco, Francesco Berardi, Mauro Niso, Roberto Perrone, Maria Antonietta Panaro, Nicola Antonio Colabufo.   

Abstract

A series of furoxan derivatives were studied for their ability to interact with P-gp and MRP1 transporters in MDCK cells overexpressing these proteins. 3-Phenylsulfonyl substituted furoxans emerged as the most interesting compounds. All of them were capable of inhibiting P-gp, and a few also were capable of inhibiting MRP1. Substituents at the 4-position of 3-phenylsulfonylfuroxan scaffold were able to modulate the selectivity and the intensity of inhibition. In some cases, they reverted MRP1 inhibitor activity, namely, they were capable of potentiating MRP1 dependent efflux. When compounds 16 and 17 were coadministered with doxorubicin, they restored a high degree of the activity of the antibiotic. Preliminary immunoblotting studies carried out on these two compounds indicate that they are capable of nitrating P-gp, which in this form is likely unable to efflux the antibiotic.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20684594     DOI: 10.1021/jm100066y

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  8 in total

1.  Light-Regulated NO Release as a Novel Strategy To Overcome Doxorubicin Multidrug Resistance.

Authors:  Konstantin Chegaev; Aurore Fraix; Elena Gazzano; Gamal Eldein F Abd-Ellatef; Marco Blangetti; Barbara Rolando; Sabrina Conoci; Chiara Riganti; Roberta Fruttero; Alberto Gasco; Salvatore Sortino
Journal:  ACS Med Chem Lett       Date:  2017-01-30       Impact factor: 4.345

2.  Nitric oxide donor doxorubicins accumulate into Doxorubicin-resistant human colon cancer cells inducing cytotoxicity.

Authors:  Konstantin Chegaev; Chiara Riganti; Loretta Lazzarato; Barbara Rolando; Stefano Guglielmo; Ivana Campia; Roberta Fruttero; Amalia Bosia; Alberto Gasco
Journal:  ACS Med Chem Lett       Date:  2011-04-04       Impact factor: 4.345

3.  New praziquantel derivatives containing NO-donor furoxans and related furazans as active agents against Schistosoma mansoni.

Authors:  Stefano Guglielmo; Daniela Cortese; Francesca Vottero; Barbara Rolando; Valerie P Kommer; David L Williams; Roberta Fruttero; Alberto Gasco
Journal:  Eur J Med Chem       Date:  2014-07-03       Impact factor: 6.514

4.  C@PA: Computer-Aided Pattern Analysis to Predict Multitarget ABC Transporter Inhibitors.

Authors:  Vigneshwaran Namasivayam; Katja Silbermann; Michael Wiese; Jens Pahnke; Sven Marcel Stefan
Journal:  J Med Chem       Date:  2021-03-16       Impact factor: 7.446

5.  Design, Synthesis, and Biological Evaluation of a Novel VEGFR-2 Inhibitor Based on a 1,2,5-Oxadiazole-2-Oxide Scaffold with MAPK Signaling Pathway Inhibition.

Authors:  Mater H Mahnashi; Fardous F El-Senduny; Mohammed Abdulrahman Alshahrani; Mahrous A Abou-Salim
Journal:  Pharmaceuticals (Basel)       Date:  2022-02-18

6.  Design, synthesis and biological evaluation of novel nitric oxide-donating podophyllotoxin derivatives as potential antiproliferative agents against multi-drug resistant leukemia cells.

Authors:  Lei Zhang; Ying Rong; Jie Zheng; Chengli Yang; Yongzheng Chen; Jing Wang; Gang Wei
Journal:  RSC Adv       Date:  2018-10-05       Impact factor: 3.361

7.  High-throughput screening against thioredoxin glutathione reductase identifies novel inhibitors with potential therapeutic value for schistosomiasis.

Authors:  Ting Li; Peter D Ziniel; Pan-Qing He; Valerie P Kommer; Gregory J Crowther; Min He; Qing Liu; Wesley C Van Voorhis; David L Williams; Ming-Wei Wang
Journal:  Infect Dis Poverty       Date:  2015-08-31       Impact factor: 4.520

Review 8.  Small and Innovative Molecules as New Strategy to Revert MDR.

Authors:  Laura Zinzi; Elena Capparelli; Mariangela Cantore; Marialessandra Contino; Marcello Leopoldo; Nicola Antonio Colabufo
Journal:  Front Oncol       Date:  2014-01-21       Impact factor: 6.244

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.